Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Policy and Pricing

Policy and Pricing

Evaluate

Thumbnail
June 30, 2023

Go or no go? Decision day looms for Eisai and Biogen

Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.

Thumbnail
June 23, 2023

Amylyx rebuff sees Europe regulators diverge from the US

Article image
Vantage logo
February 22, 2023

US deal watchdog's bark could be worse than its bite

Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?  

Article image
Vantage logo
February 09, 2023

Biopharma and Medtech Review 2022

Article image
Vantage logo
January 26, 2023

US regulator stays firm on knockbacks

Article image
Vantage logo
January 18, 2023

A year of two halves for US approvals

FDA green lights picked up in the second half, but for the really impressive number look at year-five sales.

Article image
Vantage logo
December 30, 2022

Regulatory developments over the Christmas period

The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.

Article image
Vantage logo
December 06, 2022

Illumina loses its grip

The sequencing giant’s acquisition of Grail is heading for the rocks.

Article image
Vantage logo
November 23, 2022

An expensive new haemophilia gene therapy hits the US

The approval is good for CSL, and better for Uniqure.

Article image
Vantage logo
November 10, 2022

U-turn confirms that the US cut-price oncology model is dead

EQRX tears up plans to challenge US PD-(L)1 players on price, and switches focus to two non-discounted small molecules.

Article image
Vantage logo
November 07, 2022

Verve hit by FDA’s gene editing caution

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up